TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 05/13/24

− Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression − AC Immune to receive upfront payment of $100 million upon closing and be eligible...

2024-05-10 01:27:10 ET Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Conference Call May 09, 2024 6:00 AM ET Company Participants Christopher O’Reilly – Head-Investor Relations Christophe Weber – President and Chief Execut...

2024-05-09 08:29:13 ET More on Takeda Pharmaceutical Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits New house bill to extend COVID-era telehealth flexibilities Brist...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-09 06:31:11 ET Japanese pharmaceutical titan Takeda (NYSE: TAK/TSE: 4502) today announced their financial results for Q4 and the full fiscal year of 2023. The company described it in a press release as “a year of significant loss-of-exclusivity impact”, a g...

2024-05-09 02:15:17 ET More on Takeda Pharmaceutical Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits New house bill to extend COVID-era telehealth flexibilities Brist...

Revenue Growth of +5.9% at Actual Exchange Rates (AER); +1.5% at Constant Exchange Rate (CER) Driven by Growth & Launch Products Core Operating Profit Change of -13.3% at CER Reflecting Generic Impact and Investment in R&D and Data, Digital & Technology Three N...

2024-05-08 14:10:44 ET More on Takeda Pharmaceutical Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits New house bill to extend COVID-era telehealth flexibilities Brist...

2024-05-07 15:55:56 ET More on Teladoc Health Teladoc: Even UnitedHealth Is Turning Its Back On Telehealth Teladoc: Huge Execution Problem Teladoc Health, Inc. (TDOC) Q1 2024 Earnings Call Transcript Teladoc off 3% on bottom line miss; 2024 outlook range incl...

2024-05-07 05:10:21 ET Summary Grifols, a major player in global plasma extraction and processing, has experienced a significant 43% decline in stock price in 2024 following a bearish report from Gotham. KPMG and the Spanish regulator have offered a more favorable perspective base...